Table 1

Clinical outcomes in patients with COVID-19 treated with tofacitinib

All cases<65 years old>65 years old
Population
Number of patents, n (%)320 (100)210 (66)110 (34)
Female, %504657
Mean age (range), years59 (22–96)52 (22–64)74 (65–96)
Mean treatment duration (range), days7 (1–18)6 (1–17)7 (1–18)
Dexamethasone, %30.030.030.0
Disease (on admission)
Clinical severity, %
 Mild4.73.86.4
 Moderate79.783.372.7
 Severe15.011.920.9
 Critical0.61.00.0
Lung involvement, %
 CT 00.00.00.0
 CT 110.910.012.7
 CT 265.068.658.2
 CT 322.820.028.2
 CT 41.31.40.9
C reactive protein: clinically significant abnormality, %737471
Outcomes
Death, n (%)27 (8.4)5 (2.4)22 (20.0)
Mean days from hospitalisation till death (range), days13 (4–60)17 (9–34)12 (0–33)
ICU admission, n (%)65 (20)28 (13)37 (34)
Mean stay in ICU (range), days7 (1–28)7 (1–28)7 (1–24)
Mechanical ventilation, n (%)28 (8.8)11 (5.2)17 (15.5)
Mean duration of mechanical vent. (range), days5 (1–26)9 (1–26)3 (1–6)
Safety
Thromboses, n (%)7 (2.2)2 (1.0)5 (4.6)
Pulmonary embolism, n (%)3 (0.9)0 (0.0)3 (2.7)
Infectious complications, n (%)22 (6.9)9 (4.3)13 (11.8)
  • ICU, intensive care unit.